Insight
Dickran (Diko) Kazandjian: MRD in BM precedes CR in peripheral blood necessitating new definitions of MRD negativity independently of serum markers.
Photo of Dickran Kazandjian from umiamihealth.org

Dickran (Diko) Kazandjian: MRD in BM precedes CR in peripheral blood necessitating new definitions of MRD negativity independently of serum markers

Dickran (Diko) Kazandjian, a Professor of Medicine at the Sylvester Comprehensive Cancer Center and a Board Member of OncoDaily, shared on X/Twitter:

“MRD and Plasma Cell Dynamics after CAR T-cell Therapy in Multiple Myeloma. Importantly, MRD in BM precedes CR in peripheral blood necessitating new definitions of MRD negativity independently of serum markers.”

For the original article click here.
For the editorial click here.
Source: Diko Kazandjian/Twitter

cancer CAR T-cell therapy Dikran Kazandjian Hematology multiple myeloma OncoDaily Oncology